-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA APPROVES PADCEV® PLUS KEYTRUDA® AS NEOADJUVANT AND ADJUVANT TREATMENT FOR MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITY

Reuters·07/10/2026 15:23:00

Please log in to view news